Monitor serum phosphate levels & titrate dose every 2-3 wk until an acceptable serum phosphate level is reached, w/ regular monitoring thereafter. Reports of deposition in GI mucosa, mainly after long-term use; GI obstruction, ileus, subileus, & GI perforation; serious GI complications in association w/ unchewed or incompletely chewed tab. Re-evaluate treatment in patients who develop severe constipation or other severe GI signs & symptoms. Patients w/ acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in clinical studies. Monitor serum Ca levels in patients w/ renal insufficiency who may develop hypocalcaemia. Monitor LFTs. Discontinue treatment if hypophosphataemia develops. Abdominal X-rays may have radio-opaque appearance. Patients w/ rare glucose-galactose malabsorption should not take this medicine. May impair ability to drive & use machines. Effect of hepatic impairment on Fosrenol pharmacokinetics has not been assessed. Not recommended during pregnancy. Consider benefits & risks during lactation. Safety & efficacy in childn & adolescents <18 yr have not been established.
Sign Out
